Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney diseaseLaTonya J. Hickson, James L. Kirkland, Sandra M. Herrmann et al.|EBioMedicine|2019Cited by 1.3k
Discovery, development, and future application of senolytics: theories and predictionsErin O. Wissler Gerdes, James L. Kirkland|FEBS Journal|2020Cited by 159
Corrigendum to ‘Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease’ EBioMedicine 47 (2019) 446–456LaTonya J. Hickson, James L. Kirkland, Larissa Prata et al.|EBioMedicine|2020Cited by 59